Press release
Eosinophilic Esophagitis Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Eosinophilic Esophagitis Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Eosinophilic Esophagitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Eosinophilic Esophagitis Pipeline Report
* In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
* In August 2025, Eupraxia Pharmaceuticals Inc. conducted a Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity.
* In August 2025, Uniquity One (UNI) organized a Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
* DelveInsight's Eosinophilic Esophagitis pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Eosinophilic Esophagitis treatment.
* The leading Eosinophilic Esophagitis Companies such as Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma , and others.
* Promising Eosinophilic Esophagitis Therapies such as Dupilumab, Tezepelumab, NDX-3315, Barzolvolimab, CC-93538, EP-104IAR, Budesonide , and others.
Discover how the Eosinophilic Esophagitis treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ Eosinophilic Esophagitis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eosinophilic Esophagitis Emerging Drugs Profile
* APT-1011: Ellodi Pharmaceuticals
APT-1011 is a novel, proprietary, once daily, investigational oral disintegrating tablet designed to deliver fluticasone propionate to the esophageal mucosa while minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 reduced esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. It is currently in clinical development, following successful completion of FLUTE I and FLUTE II. It has been granted orphan drug status by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis.
* IRL201104: Revolo Biotherapeutics
IRL201104, is uniquely safe and efficacious demonstrating immunoregulatory activity in a number of preclinical models. It has successfully completed Phase I clinical development and has the potential to be the first Immune Resetting Asthma Drug (IMRAD). 1104 is a novel linear peptide, derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It may provide remission for many allergic diseases. 1104 engages a novel target on macrophages and is a first-in-class modulator of the macrophage response. This response engages not only the effector arm of the immune system, but the regulatory arm as well. Currently the product is in Phase II stage of development for the treatment of patients with eosinophilic esophagitis (EoE) and other Th2 allergic diseases.
* AQ280: Aqilion
AQ280 is an oral, small-molecule, super selective JAK1 inhibitor. JAK1 is an enzyme, a kinase that accelerates inflammatory processes, which, among other things effects allergy and fibrosis. By inhibiting its mechanism, it is possible to reduce symptoms and disease development in chronic inflammatory diseases. Within the Regulus program, Aqilion is developing AQ280, which is a super selective JAK1 inhibitor, as a treatment of the chronic disease eosinophilic esophagitis. Data describing the pharmacokinetic profile, safety and tolerability of the drug candidate was evaluated between every dose escalation. Now, data has been collected for all dose groups and the database has been locked for statistical analysis. Currently the product is in Phase I stage of development for the treatment of patients with eosinophilic esophagitis (EoE).
The Eosinophilic Esophagitis pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Esophagitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Esophagitis Treatment.
* Eosinophilic Esophagitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Eosinophilic Esophagitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Esophagitis market.
Get a detailed analysis of the latest innovations in the Eosinophilic Esophagitis pipeline. Explore DelveInsight's expert-driven report today! @ Eosinophilic Esophagitis Unmet Needs [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eosinophilic Esophagitis Companies
Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma , and others.
Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
Eosinophilic Esophagitis Products have been categorized under various Molecule types such as
* Peptide
* Protein
* Propylene glycols
* Cell Therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Eosinophilic Esophagitis Therapies and key drug developments @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Eosinophilic Esophagitis Pipeline Report
* Coverage- Global
* Eosinophilic Esophagitis Companies- Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma , and others.
* Eosinophilic Esophagitis Therapies- Dupilumab, Tezepelumab, NDX-3315, Barzolvolimab, CC-93538, EP-104IAR, Budesonide , and others.
* Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Eosinophilic Esophagitis drug development? Find out in DelveInsight's exclusive Eosinophilic Esophagitis Pipeline Report-access it now! @ Eosinophilic Esophagitis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Eosinophilic Esophagitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Eosinophilic Esophagitis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* APT-1011: Ellodi Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IRL201104: Revolo Biotherapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AQ280: Aqilion
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Eosinophilic Esophagitis Key Companies
* Eosinophilic Esophagitis Key Products
* Eosinophilic Esophagitis- Unmet Needs
* Eosinophilic Esophagitis- Market Drivers and Barriers
* Eosinophilic Esophagitis- Future Perspectives and Conclusion
* Eosinophilic Esophagitis Analyst Views
* Eosinophilic Esophagitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-esophagitis-pipeline-outlook-report-2025-key-25-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eosinophilic Esophagitis Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4144537 • Views: …
More Releases from ABNewswire
North Texas Homeowners Turn to Fort Tex Metals & Roofing for Reliable Roof Repai …
Fort Tex Metals & Roofing provides certified roofing services across DFW, offering tiered options, insurance claim support, and a referral-driven reputation backed by 162 five-star Google reviews.
Storm season across the Dallas-Fort Worth region has left thousands of property owners assessing damage and weighing their options. With hail, high winds, and severe weather becoming more frequent in North Texas, the demand for dependable roofing services has surged. Fort Tex Metals &…
Long Distance Movers at Daymakers Moving and Storage Set a New Standard for Safe …
Daymakers Moving and Storage in Hudson, WI, provides full-service relocation support for cross-state moves, including packing, transport, and storage, with transparent pricing for residential and commercial clients.
The demand for professional relocation support continues to climb as more families and businesses move between states for work, lifestyle changes, and housing affordability. In Hudson, WI, one company has been quietly building a track record that speaks for itself. Daymakers Moving and Storage…
Bloomington Businesses Turn to Professional Office Movers for Smoother Transitio …
Daymakers Moving and Storage provides professional commercial relocation services in Bloomington, MN, with private trucks, real-time tracking, and climate-controlled storage for businesses across the Twin Cities.
The demand for commercial relocation support in Bloomington, MN, continues to rise as local businesses expand, downsize, or relocate. For companies navigating these changes, moving an entire operation without losing productivity has become a serious concern. That's where Daymakers Moving and Storage [https://daymakersmoving.com/bloomington-mn-movers/] steps in…
How Daymakers Moving and Storage Is Changing the Game for Commercial Relocations …
Daymakers Moving and Storage offers Roseville, MN businesses a full-service commercial relocation experience backed by 800+ five-star reviews, transparent pricing, and multi-location reach across the Twin Cities metro.
Business relocations across the Twin Cities metro are on the rise, and companies in Roseville, MN, are turning to experienced professionals to handle the heavy lifting. Daymakers Moving and Storage [https://daymakersmoving.com/roseville-mn-movers/?] has positioned itself as a reliable option for organizations that need efficient,…
More Releases for Eosinophilic
Eosinophilic Esophagitis Market to Surge to USD 4.1 Billion by 2034
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus, characterized by eosinophil infiltration, difficulty swallowing, food impaction, and chest pain. Once considered rare, EoE has now emerged as one of the most common causes of dysphagia in children and adults, particularly in developed nations. Strong associations with allergic conditions such as asthma, eczema, and food allergies underscore its complex immunological nature.
Download Full PDF Sample Copy of Market…
Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2030
The eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Esophagitis Pipeline, Clinical Trials Assessment, Emerging Therapie …
DelveInsight's, "Eosinophilic Esophagitis Pipeline Insight" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Eosinophilic Esophagitis research. Learn more about…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Granulomatosis Treatment Market Size and Overview Upto 2028|
The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Eosinophilic Granulomatosis Treatment market. It includes Porter's Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Eosinophilic Granulomatosis Treatment Market. We have provided a deep analysis of the vendor landscape to give…
